Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care. 

Medtronic announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition. 

Scientia is a private company operating in Salt Lake City, Utah. The company has developed access products that enable simplicity and access for physicians treating complex neurovascular conditions. It seamlessly integrated with Medtronic's existing suite of neurovascular products, strengthening the company's ability to support physicians across the full procedural workflow. 

According to Towards Healthcare, the intracranial aneurysm market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.66 billion in 2026 to approximately USD 5.64 billion by 2035, representing a compound annual growth rate (CAGR) of 8.7% from 2026 to 2035. Growth is driven by the rising incidence of hypertension, smoking, alcohol consumption, genetic predisposition, and an ageing population, which is contributing to the growth of the market. There is a growing awareness among clinicians and patients about the risks associated with untreated brain aneurysms, which leads to higher adoption of the therapeutic procedures. 

About the Neurovascular Business at Medtronic  

Medtronic Neurovascular is dedicated to expanding access to neurovascular therapies through innovation and globalisation, supported by strategic investments in remote connectivity and the development of the Medtronic Neurovascular Co-Lab Platform, which serves as an incubator for advancing stroke care and treatment. 

Together with our partners, including physicians, hospitals, governments, and patients, we're expanding into new disease states and stages of care. Our unwavering focus on better outcomes fuels our drive to deliver life-changing therapies and transform the future of care for patients worldwide.  

About Medtronic 

The company aims to improve the lives of millions of people each year through its innovative medical technologies and solutions. The company collaborates with healthcare professionals and organisations to develop solutions that enhance patient care and outcomes. It stands out as a leader in the medical device industry, continuously innovating to improve healthcare and patient lives globally. 

A recent report by Towards Healthcare highlights that intracranial aneurysm market is witnessing growth, due to the significant growth, driven by the increasing prevalence of cerebrovascular disorders and the demand for effective treatment solutions. Focusing on innovation and research to introduce novel products that support the treatment of this disease. 

The North America region is expected to dominate the intracranial aneurysm market with a significant revenue share, reflecting a mature ecosystem built around comprehensive stroke centres and iterative device upgrades. The Asia-Pacific region is projected to be the fastest-growing, driven by improved imaging penetration and interventional capacity expansion.